CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
GDR3697 Micronit, CNRS, Nantes, France.
Leukemia. 2019 Oct;33(10):2442-2453. doi: 10.1038/s41375-019-0463-3. Epub 2019 Apr 2.
The microenvironment strongly influences mantle cell lymphoma (MCL) survival, proliferation, and chemoresistance. However, little is known regarding the molecular characterization of lymphoma niches. Here, we focused on the interplay between MCL cells and the associated monocytes/macrophages. Using circulating MCL cells (n = 58), we showed that, through the secretion of CSF1 and, to a lesser extent, IL-10, MCL polarized monocytes into specific CD163 M2-like macrophages (MϕMCL). In turn, MϕMCL favored lymphoma survival and proliferation ex vivo. We next demonstrated that BTK inhibition abrogated CSF1 and IL-10 production in MCL cells, leading to the inhibition of macrophage polarization and consequently resulting in the suppression of microenvironment-dependent MCL expansion. In vivo, we showed that CSF1 and IL-10 plasma concentrations were higher in MCL patients than in healthy donors, and that monocytes from MCL patients overexpressed CD163. Further analyses of serial samples from ibrutinib-treated patients (n = 8) highlighted a rapid decrease of CSF1, IL-10, and CD163 in responsive patients. Finally, we showed that targeting the CSF1R abrogated MϕMCL-dependent MCL survival, irrespective of their sensitivity to ibrutinib. These data reinforced the role of the microenvironment in lymphoma and suggested that macrophages are a potential target for developing novel therapeutic strategies in MCL.
肿瘤微环境强烈影响套细胞淋巴瘤(MCL)的存活、增殖和化疗耐药性。然而,关于淋巴瘤龛位的分子特征知之甚少。在这里,我们专注于 MCL 细胞与相关单核细胞/巨噬细胞之间的相互作用。我们使用循环中的 MCL 细胞(n=58),表明通过 CSF1 的分泌,并且在较小程度上通过 IL-10,MCL 使单核细胞极化为特定的 CD163 M2 样巨噬细胞(MϕMCL)。反过来,MϕMCL 有利于体外淋巴瘤的存活和增殖。我们接下来证明 BTK 抑制可阻断 MCL 细胞中 CSF1 和 IL-10 的产生,导致巨噬细胞极化的抑制,从而抑制依赖微环境的 MCL 扩增。在体内,我们发现 MCL 患者的 CSF1 和 IL-10 血浆浓度高于健康供体,并且 MCL 患者的单核细胞过度表达 CD163。对接受伊布替尼治疗的患者(n=8)的连续样本进行的进一步分析突出显示,在有反应的患者中,CSF1、IL-10 和 CD163 迅速减少。最后,我们表明,靶向 CSF1R 可消除 MϕMCL 依赖性 MCL 存活,而与它们对伊布替尼的敏感性无关。这些数据强化了肿瘤微环境在淋巴瘤中的作用,并表明巨噬细胞是开发 MCL 新型治疗策略的潜在靶标。